PMID- 28421161
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240325
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 7
DP  - 2017
TI  - Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and 
      Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers.
PG  - 56
LID - 10.3389/fonc.2017.00056 [doi]
LID - 56
AB  - Program death receptor-1 (PD-1) and program death receptor-1 ligand (PD-L1) 
      inhibitors are increasingly being used in the clinic to treat a growing number of 
      malignancies, including many genitourinary (GU) malignancies. These immune-based 
      therapies have demonstrated a distinct toxicity profile compared to traditional 
      chemotherapy and the targeted therapies directed at the vascular endothelial 
      growth factor pathway or the mammalian target of rapamycin pathway. Autoimmune 
      toxicity targeting the skin, gastrointestinal tract, or the endocrine organs are 
      some of the more common adverse events (AEs) noted with these therapies. Here in, 
      we report the results of a systematic review of the incidence of toxicities in GU 
      cancers reported in the phase II or phase III clinical trials using single-agent 
      PD-1 or PD-L1 inhibitors. Overall, the rate of serious (grades 3-4) AEs was noted 
      in approximately 15% of patients. The AEs noted were similar between all the 
      agents tested, highlighting the overall class effect of these therapies. The 
      incidence in GU cancers is similar to those seen in other malignancies. Given the 
      widespread and high volume real-world use of these agents, it is important for 
      oncologists to be familiar with these side effects to minimize the risks for 
      patients while undergoing therapy.
FAU - Maughan, Benjamin L
AU  - Maughan BL
AD  - Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
AD  - Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
FAU - Bailey, Erin
AU  - Bailey E
AD  - Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
FAU - Gill, David M
AU  - Gill DM
AD  - Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
FAU - Agarwal, Neeraj
AU  - Agarwal N
AD  - Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
AD  - Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170403
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC5377000
OTO - NOTNLM
OT  - autoimmune
OT  - checkpoint blockade
OT  - immune-related adverse events
OT  - immunotherapy
OT  - toxicity
OT  - treatment
EDAT- 2017/04/20 06:00
MHDA- 2017/04/20 06:01
PMCR- 2017/01/01
CRDT- 2017/04/20 06:00
PHST- 2017/01/30 00:00 [received]
PHST- 2017/03/14 00:00 [accepted]
PHST- 2017/04/20 06:00 [entrez]
PHST- 2017/04/20 06:00 [pubmed]
PHST- 2017/04/20 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2017.00056 [doi]
PST - epublish
SO  - Front Oncol. 2017 Apr 3;7:56. doi: 10.3389/fonc.2017.00056. eCollection 2017.